Loading ...Pfizer’s Covid-19 Pill Failed Study Testing Its Preventive Use – Wall Street Journal
Paxlovid, authorized to treat high-risk people early in infection, didn’t meaningfully reduce illness in exposed adults
Pfizer said Friday that the drug, named Paxlovid, failed the study’s main objective of meaningfully reducing the risk of confirmed and symptomatic Covid-19 infections in adults who were exposed to the virus by someone in their household.
Paxlovid was cleared for use in December by U.S. health regulators to treat people 12 years and older early in the course of their disease who are at high risk of developing severe Covid-19.